Cefaclor

Cefixime is an oral third generation cephalosporin antibiotic. It was sold under the trade name suprax in the usa, until 2003 when it was taken off the market by drug manufacturer wyeth after its patent expired. The oral suspension form of "suprax" was re-launched by lupin in the usa. Cefixime is still available in canada. It is used to treat gonorrhea, tonsilitis, and pharyngitis.

Cefprozil, sometimes spelled cefproxil and sold under the brand name Cefzil, is a cephalosporin type antibiotic. In Europe, it is sold by the name Procef. It can be used to treat bronchitis, ear infections, skin infections, and other bacterial infections. It comes as a tablet and as a liquid suspension. Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article in the Journal of Family Practice (February 2006) has shown no increased risk for cross-allergy for cefprozil and several other 2nd generation or later cephalosporins.

Cefuroxime is a second-generation cephalosporin antibiotic that has been widely available in the usa since 1977. It is also available under the brand name ceftin. Glaxo smith kline sells the antibiotic in australia (and other countries, such as cyprus, israel and poland) under the name zinnat[1], with the australian pharmaceutical code of r 47621. In the philippines, a brand name shincef has been used. In poland it is also produced by the polish firm bioton s. A. Under the name biofuroksym. [2] in cyprus, the box of the 500mg tablets is white with a wide red stripe on the left and contains two blister cards of seven. The tablets are long white and are marked "gx eg2". The cypriot license for this is 16847. The 250mg tablets come in a similar box with a blue stripe.

Dosage by mouth for adults is 250-500 mg every 6 hours, or 500 mg to 1 g every 12 hours. In severe infections up to 1 g every 6 hours may be used. Dosages for children are based upon their weight with 25-50 mg/kg total daily dose given in 2-4 divided doses.